千金药业：公司及子公司获得药品注册证书

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the National Medical Products Administration for the registration of Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), which will enhance the company's product pipeline and support sustainable development [1] Group 1 - The approval of these drugs will enrich the company's product offerings [1] - The new products are expected to contribute positively to the company's growth and sustainability [1] - There are uncertainties related to drug production and sales due to policy and market environment factors [1]